'We Have The Means To Prevent 80% Heart Attacks And Strokes', Expert Urges NHS To Give 'Polypill'

Updated Mar 6, 2025 | 05:00 AM IST

SummaryA polypill combining statins and blood pressure drugs could prevent 80% of heart attacks and strokes. Research shows it cuts cardiovascular risk by a third, benefiting millions globally with minimal side effects.
'We Have The Means To Prevent 80% Heart Attacks And Strokes', Expert Urges NHS To Give 'Polypill'

Image Credits: Canva

Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

End of Article

After US Loses Measles Elimination Status, Senators Call Out RFK Jr. Over Vaccine Policies

Updated Nov 19, 2026 | 06:00 PM IST

SummaryThe Pan American Health Organization (PAHO) confirmed that the US had lost the status it maintained since 2000. ​The country has recorded more than 5,700 measles cases and 11 deaths. Pennsylvania, the hardest-hit state, has reported its eighth measles-associated death of 2026.
After US Loses Measles Elimination Status, Senators Call Out RFK Jr. Over Vaccine Policies

Credit: AP Photos

After 26 years, the US has lost its measles elimination status, marking a major setback for public health efforts. The resurgence has intensified criticism of Health and Human Services Secretary Robert F. Kennedy Jr. over his vaccine policies and rhetoric.

The Pan American Health Organization (PAHO) confirmed that the US had lost the status it maintained since 2000.

The country has recorded more than 5,700 measles cases and 11 deaths. Pennsylvania, the hardest-hit state, has reported its eighth measles-associated death of 2026.

Measles Infections Among Pregnant Women, Newborns Raise Concern

A CDC-led report identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns.

The actual number may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.

“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.

Decades of MMR vaccination meant many doctors had never encountered measles during their medical careers. However, declining vaccination rates have allowed the disease to spread in under-vaccinated communities.

US Senators Criticise RFK Jr.

Criticism of Kennedy has crossed party lines. Republican Senator Bill Cassidy of Louisiana on Sunday criticised what he called a "series of failures" under Kennedy's leadership at the Department of Health and Human Services.

"This has been a failure. If I were president, I would choose someone else because there needs to be accountability for higher health care costs, more measles deaths, losing elimination status, and no progress on processed foods," Cassidy said on CBS News.

Democratic senators Angela Alsobrooks and Patty Murray have also called for Kennedy's removal.

Alsobrooks (Maryland) condemned the loss of measles elimination status and called Kennedy's tenure a disgrace. She had called for his resignation or dismissal in May 2025. Her resolution of disapproval against Kennedy now has 28 Senate co-sponsors.

Senator Richard Blumenthal (Connecticut) has demanded answers over the alleged suppression of a CDC warning about measles risks during pregnancy, while criticising the administration's vaccine policies.

Murray (Washington) has blamed Trump and Kennedy's leadership for the loss of elimination status and repeatedly called for Kennedy's removal.

Governors Demand Kennedy's Removal

Democratic governors have also blamed Kennedy for the setback. New York Governor Kathy Hochul said the loss of measles elimination status contradicted Kennedy's promise to make America healthy again.

"RFK Jr. promised to 'Make America Healthy Again.' Now America has lost its measles-free status for the first time in 26 years," Hochul said.

"A disgraceful display of incompetence from the nation's highest public health office," she added.

Pennsylvania Governor Josh Shapiro blamed vaccine misinformation and skepticism for the setback. "There is a clear line from the misinformation, vaccine skepticism, and incompetence of RFK Jr. to this devastating news and very real consequences," Shapiro said.

Kentucky Governor Andy Beshear explicitly demanded Kennedy's removal. "This dangerous setback was 100% avoidable and is the result of one person: RFK Jr.," Beshear said. "Remove him now."

An HHS spokesperson rejected the governors' criticism in a statement to Fox News Digital, calling their attacks "baseless" and arguing that declining vaccination rates predated the Trump administration.

The spokesperson said the administration remained focused on expanding vaccine access, closing immunisation gaps and assisting state and local officials with outbreak investigations.

What Has RFK Jr. Said?

Kennedy has vowed to stop measles outbreaks and restore the country's elimination status while continuing to recommend vaccination.

"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," Kennedy said in a statement.

"I continue to recommend MMR vaccination as the most effective way to prevent measles," he added.

End of Article

Hope For Alzheimer's-Related Psychosis? Schizophrenia Drug Reduces Hallucinations & Delusions In Recent Trial

Updated Nov 19, 2026 | 08:00 PM IST

SummaryBristol Myers Squibb's schizophrenia drug Cobenfy, made by combining xanomeline and trospium chloride, reportedly showed promising results in controlling psychosis symptoms in patients with Alzheimer's disease.
Schizophrenia Drug Shows Promise Against Hallucinations And Delusions In Alzheimer's Patients

Credit: AI

A schizophrenia drug has reportedly proven effective in fighting manic symptoms like hallucinations and delusions that accompany Alzheimer's disease. The finding has sparked hope to treat one of the most distressing symptoms complications of dementia.

The drug, Cobenfy (xanomeline and trospium chloride), developed by Bristol Myers Squibb (BMS), is currently being investigated for treating psychosis that patients with Alzheimer's disease may experience. The preliminary findings from two Phase 3 clinical studies showed improvements in hallucinations, delusions and the severity of the overall disease among participants who received the drug.

The findings were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. Cobenfy is currently approved in the US for schizophrenia in adults, not for Alzheimer's-induced psychosis.

Findings From The Clinical Trial

Also read: Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?

The findings came from two studies within BMS's Phase 3 ADEPT clinical development programme.

In the ADEPT-1 study, 273 participants completed a 12-week treatment period in which patients knew they received Cobenfy.

Researchers observed a mean reduction of 12 points in participants' hallucination and delusion scores, which was measured using the Neuropsychiatric Inventory-Clinician (NPI-C) scale. Their overall scores of disease severity also improved.

A separate study, ADEPT-3, evaluated long-term safety and tolerability of the drug. Among 401 participants, 273 completed the 52-week treatment period. Their hallucination and delusion scores also improved.

However, these findings came from open-label treatment trials, which means that participants and researchers knew that the drug was being administered. More reliable evidence will come from the blinded parts of the ADEPT programme, which evaluate the treatment's efficacy against a control group.

What Is Alzheimer's-Related Psychosis?

Also read: 'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Alzheimer's disease is a progressive neurological condition that damages brain cells and gradually affects memory, thinking, behaviour and the ability to perform everyday activities. Some people with Alzheimer's also develop psychosis, which can present with symptoms like hallucinations and delusions.

Hallucinations occur when someone sees, hears or experiences things that are not actually present. For instance, a person may see people around them who are not actually there or hear voices that others cannot hear.

Delusions involve strongly believing something that is not true. For example, an Alzheimer's patient with psychosis may be convinced that family members are stealing from them, that their partner is being unfaithful or that someone is trying to harm them.

According to BMS, approximately 30–50% of people with Alzheimer's experience psychosis during the course of the disease.

These symptoms can be distressing for patients as well as caregivers. Researchers also observed faster cognitive and functional decline in patients with psychosis. This increased caregiver burden and a greater likelihood of institutionalisation.

Despite the severity of Alzheimer's-induced psychosis, there are currently no FDA-approved medicines for treating it.

More About Cobenfy

Cobenfy works differently from other antipsychotic medicines, which usually target dopamine receptors in the brain. Cobenfycombines two drugs: xanomeline and trospium chloride.

Xanomeline activates muscarinic receptors, specifically M1 and M4 receptors, which regulate communication between brain cells, cognition and behaviour. By targeting these receptors, xanomeline regulates parts of brain that are involved in psychiatric symptoms.

Trospium chloride is added to reduce unwanted effects of xanomeline outside the brain, especially those involving the peripheral nervous system.

In the 12-week ADEPT-1 treatment period, 56.6% of participants experienced at least one adverse event due to the drug. Serious adverse events were reported in 5% of participants, while 4.4% stopped the treatment because of side effects.

In the longer-term ADEPT-3 study, adverse events were reported in 65.1% of participants, serious adverse events in 7.7%, and discontinuations due to adverse events in 4.7%.

Cobenfy remains investigational for its use for Alzheimer's-related psychosis. The ongoing ADEPT programme includes more studies to assess its efficacy , dose and long-term safety. BMS is expected to share further findings along with important results placebo-based trials.

End of Article

India To Track 4 Infectious Disease Syndromes Across 70 Labs For Early Outbreak Warnings: How It Will Work

Updated Nov 19, 2026 | 07:00 PM IST

SummaryThe ICMR has launched a syndromic surveillance network across 70 VRDLs and IRDLs to strengthen early detection of infectious disease outbreaks and improve public health preparedness.
India To Track 4 Infectious Disease Syndromes Across 70 Labs For Early Outbreak Warnings: How It Will Work

Credit: iStock

India is strengthening its early-warning system for infectious disease outbreaks through a network of 70 Virus Research and Diagnostic Laboratories (VRDLs) and Infectious Disease Research and Diagnostic Laboratories (IRDLs).

Led by the Department of Health Research (DHR) and the Indian Council of Medical Research (ICMR), the initiative will introduce syndromic surveillance using real-time or near-real-time health data to identify potential outbreaks.

The initiative was launched at the third DHR-ICMR Health Research Excellence Summit.

"Syndromic Surveillance under the DHR Virus Research and Diagnostic Laboratories (VRDL) Scheme will create an early-warning network for outbreaks across 70 VRDLs and Infectious Disease Research & Diagnostic Laboratories (IRDLs)," ICMR announced.

The network will support epidemiological investigations and help authorities assess an outbreak's scale, geographical spread and speed of transmission.

Which 4 Infectious Disease Syndromes Will India Track?

Also read: ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

As reported by Hindustan Times, the surveillance framework will focus on four major infectious disease syndromes:

  • Acute Febrile Illness (AFI): Including acute undifferentiated fever, fever with rash and fever with lymphadenopathy.
  • Acute Encephalitis Syndrome (AES): Conditions involving inflammation of the brain, often linked to infections.
  • Acute Respiratory Illness: Infections affecting the respiratory system.
  • Acute Diarrhoeal Disease: Infections causing diarrhoea.

ICMR has prepared syndrome-specific priority pathogen lists to guide doctors, laboratory specialists, epidemiologists and policymakers on testing and surveillance.

Why Does India Need Standardised Pathogen Testing?

A document outlining the framework, seen by the media outlet, points to limited countrywide data on pathogen prevalence and trends to guide surveillance policies.

As testing protocols differ between institutions and regions, many follow disease-specific approaches and sequential testing, leading to "missing out on common or critical pathogens".

Such gaps can hamper patient care and aggravate public health challenges, including antimicrobial resistance (AMR).

To address this, ICMR has identified priority pathogens responsible for critical infectious disease syndromes in India.

Read More: New COVID Variant PJ.2.1 Spreading Globally: Is India At Risk, Are There New Symptoms?

How Will ICMR Prioritise Infectious Disease Pathogens?

The priority lists were developed through 44 meetings involving clinicians, laboratory specialists and epidemiologists from across the country, the report said.

Expert groups reviewed scientific literature from India and similar settings, considering pathogen prevalence, emerging trends, outbreak potential, disease elimination targets and the availability of diagnostics and treatments.

The pathogens have been classified into four categories:

  • Priority 1A: Commonly detected pathogens that are important to identify before starting treatment.
  • Priority 1B: Other commonly detected pathogens in clinical settings.
  • Priority 2: Less common pathogens found in clinical settings.
  • Priority 3: Rare pathogens that may require specialised laboratory testing and surveillance.

Testing priorities will also depend on local and seasonal risks. Endemic pathogens will receive greater attention in affected regions, while outbreak-prone infections will be prioritised during outbreaks. Seasonal pathogens will be given greater attention during periods such as the post-monsoon and flooding seasons.

Animal exposure, including contact with cats, rats and rabbits, and suspected exotic infections will also influence testing priorities.

The initiative aims to improve pathogen detection, strengthen clinical diagnosis and help authorities identify unusual disease patterns before they escalate into larger outbreaks.

End of Article